Citizens Jmp Raises Zevra Therapeutics (NASDAQ:ZVRA) Price Target to $28.00

Zevra Therapeutics (NASDAQ:ZVRA) had its price target hoisted by stock analysts at Citizens Jmp from $25.00 to $28.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s price target points to a potential upside of 142.21% from the company’s previous close.

A number of other equities analysts also recently commented on ZVRA. BTIG Research dropped their target price on shares of Zevra Therapeutics from $27.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Maxim Group lifted their price target on shares of Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Cantor Fitzgerald boosted their price target on Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a report on Monday, June 8th. Guggenheim dropped their price objective on Zevra Therapeutics from $29.00 to $24.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Finally, Canaccord Genuity Group cut their price target on Zevra Therapeutics from $29.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, July 27th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $27.14.

Zevra Therapeutics Stock Down 2.7%

Shares of Zevra Therapeutics stock opened at $11.56 on Thursday. The stock’s fifty day moving average is $12.32 and its two-hundred day moving average is $10.58. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $15.03. The company has a market capitalization of $686.43 million, a PE ratio of 12.57 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.14. The firm had revenue of $39.66 million during the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a net margin of 42.82% and a return on equity of 54.54%. As a group, research analysts anticipate that Zevra Therapeutics will post 0.59 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ZVRA. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $53,000. Russell Investments Group Ltd. lifted its position in Zevra Therapeutics by 235.7% during the third quarter. Russell Investments Group Ltd. now owns 6,374 shares of the company’s stock valued at $61,000 after purchasing an additional 4,475 shares during the period. Tower Research Capital LLC TRC lifted its position in Zevra Therapeutics by 617.5% during the second quarter. Tower Research Capital LLC TRC now owns 9,937 shares of the company’s stock valued at $88,000 after purchasing an additional 8,552 shares during the period. Creative Planning purchased a new stake in Zevra Therapeutics in the second quarter valued at $92,000. Finally, Qube Research & Technologies Ltd acquired a new stake in Zevra Therapeutics during the 2nd quarter worth about $99,000. 35.03% of the stock is owned by institutional investors and hedge funds.

More Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Zevra reported quarterly EPS of $0.25 versus the $0.11 consensus estimate, while revenue reached $39.66 million, above expectations of $33.88 million. The company also posted a 42.82% net margin and positive operating cash flow. Zevra Therapeutics quarterly earnings report
• Positive Sentiment: Analysts remain bullish. Citizens raised its price target from $25 to $28 and assigned a “market outperform” rating. HC Wainwright maintained a “Buy” rating and a $26 target, while increasing its FY2026 EPS forecast to $0.57 from $0.55. Citizens price-target update
• Positive Sentiment: Regulatory and intellectual-property developments could improve MIPLYFFA’s long-term outlook. Zevra outlined a timeline for a CHMP reexamination opinion expected in the fourth quarter, while its MIPLYFFA Orange Book listing reportedly extends to 2041. Zevra CHMP and Orange Book update
• Neutral Sentiment: Guggenheim trimmed its price target to $23 from $24 but retained a “Buy” rating, leaving a target substantially above the current trading level. Guggenheim price-target update
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $0.13 from $0.17, signaling weaker near-term earnings expectations despite raising its full-year forecast.
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of ZVRA investors. Although no allegations or findings were detailed, the announcement introduces legal and reputational overhang. Pomerantz investor investigation

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.